A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers. (NCT04086823), a randomized phase 2 study. The primary outcome is Safety: Adverse Events Follow up.

2. Clinical Question

In statistical terms, the question is whether adverse events were observed among participants in the RZL-012 cohorts and the corresponding placebo cohorts during the defined follow-up. The record reports participant counts, including counts with serious and other adverse events. These counts describe what was recorded in this small study; they do not by themselves establish whether event rates differ between treatments. The study also lists physician’s global assessment, MRI volume reduction and face satisfaction as secondary outcomes, but their numerical results are not reported in the registry record.

3. Trial Design

This was a randomized, single-blind, parallel-group Phase 2a study of RZL-012 and placebo for submental fat in healthy volunteers. The registry record lists the study as completed, with enrollment of 28. It gives a start date of 2020-02-25 and a primary completion date of 2020-09-16. The brief summary describes two cohorts: 12 subjects in cohort 1 and 16 in cohort 2, with subjects in each cohort receiving a different RZL-012 dose. The record says enrollment took place at two clinical sites.

The posted primary outcome contains four groups: RZL-012 Cohort 1, Vehicle Cohort 1, RZL-012 Cohort 2 and Vehicle Cohort 2. The reported group counts are 8, 4, 10 and 6 participants, respectively. Keeping the cohorts distinct matters: the study was not presented as a single two-arm comparison with one RZL-012 dose. The record describes RZL-012 injections at 48 submental sites and describes placebo injections at 48 sites. It gives different placebo volume limits for the cohorts. Full injection details are not reported in the registry record.

Single blinding means the record identifies the study as blinded for one party, but does not specify who was blinded. The randomization method, allocation concealment procedures and blinding procedures are not reported in the registry record. The number assigned to each group and the number represented in the posted outcome counts are consistent with the stated cohort enrollment, but the record does not provide a participant-flow account describing screening, withdrawals or missing follow-up.

The stated design can support descriptive safety summaries by cohort and treatment. A reliable treatment contrast would require clear outcome definitions, denominators, suitable uncertainty estimates and an analysis plan. Such comparative analyses are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: The safety and efficacy of exposed subjects to RZL-012 were compared to exposed subjects with placebo

Overall Study

Analysis population for the primary outcome, as defined in the registry: Safety Analysis consist of all enrolled subjects who received the study treatment, (exposed population), vs. placebo treated subjects.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Baseline is defined as the last available and evaluable parameter value before and closest to the injection.

6. Primary Endpoint

The registry lists the primary outcome as Safety: Adverse Events Follow up, measured over 0-84 days.

The primary outcome is titled “Safety: Adverse Events Follow up.” It is a participant-count outcome, with a timeframe of 0-84 days. The stated purpose is to evaluate the safety of subcutaneous RZL-012 injections in the submental area relative to placebo. Assessment is described as spontaneous adverse-event reports and post-injection evaluations. Pain, induration, bruising, erythema and edema are named for close follow-up.

A participant count answers how many people in a group were recorded as having an event under the outcome definition. It is not the same as an event count: one person can experience more than one event, while a participant-level count generally counts each person rather than every occurrence. The record does not explain in detail how multiple events in one participant were handled for this outcome or whether the posted count represents any adverse event, specific symptoms, or another defined event category. The adverse-event results separately report participants with serious adverse events and participants with other adverse events.

Safety monitoring is appropriate to a study evaluating an injectable intervention because it records unwanted events after administration and permits descriptive review by treatment group. However, counts alone do not establish whether an event was caused by treatment. Nor do they show the timing, duration, intensity or clinical consequences of each event. Those details are not reported in the registry record. The outcome therefore supports a bounded description of recorded events during follow-up, rather than a complete account of safety or a definitive comparative conclusion.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a participant count mean?

A participant-count endpoint records how many people meet an outcome definition. In this study, the primary outcome is a safety follow-up count, while the adverse-event record separates serious events from other events. A count is easiest to interpret alongside its denominator: for example, the record reports both the number affected and the number at risk in each group. Those two quantities describe the observed data; they do not alone quantify uncertainty or establish a treatment effect.

The distinction between participants and events is important. A participant may report multiple adverse events, but a participant-level count does not necessarily indicate how many total events occurred. The registry record does not give event totals or provide detailed rules for classifying participants with multiple events. It also does not report event-level timing, duration or severity for the other adverse events.

Why are the cohorts kept separate?

The study has two cohorts, and the record says participants in each cohort received a different RZL-012 dose. The posted outcome groups retain cohort identity for both RZL-012 and Vehicle. This makes the group counts interpretable in the context of the study structure. Pooling all RZL-012 participants and comparing them with all placebo participants could be misleading if dose, cohort procedures or placebo volumes differ. A pooled analysis would need to specify how cohort is handled and why that approach is appropriate; such an analysis plan is not reported in the registry record.

What would a treatment comparison add?

A formal comparison would estimate a difference or another contrast between groups, rather than simply listing counts. An uncertainty interval around that estimate would describe the range of effects compatible with the data under the analysis assumptions. A confidence interval is a general statistical tool for expressing uncertainty; it is not reported for these outcome counts. A p-value, also not reported, addresses compatibility with a specified statistical hypothesis and does not measure the size or importance of an effect. Without these comparative quantities, the observed counts cannot establish whether the groups differ.

For a binary outcome, sparse counts can make conventional approximations unreliable. General statistical methods may use exact procedures or other approaches suited to small samples, but the method selected depends on the endpoint and analysis plan. The analysis method is not reported in the registry record. The absence of serious events in all groups also means the posted counts do not yield an informative observed contrast for serious events; zero counts should not be interpreted as proof of no underlying risk.

Why does over-dispersion matter?

General explanation: over-dispersion occurs when observed variability is greater than a model assumes. For event-count outcomes, a model that assumes a fixed relationship between the mean and variability can understate uncertainty if participants differ substantially in their event burden. That can make intervals too narrow and tests too optimistic. The present primary outcome is reported as a participant count, and the registry record does not provide event totals or a model-based analysis, so over-dispersion cannot be assessed from the posted summary.

What can sample-size planning illustrations tell readers?

General explanation: a sample-size calculation describes the number of participants a hypothetical design might need under stated assumptions, such as a target effect, significance level, allocation, and statistical model. It is a planning exercise, not a measure of what the completed trial was capable of detecting after the results are known. It is not “observed power.” The registry record’s stated planning assumptions refer to a two-sided significance level of 0.05, equal allocation, a normal approximation and effects expressed as fractions of an observed effect. These assumptions describe an illustration, not the trial’s own design justification. The trial’s sample-size justification is not reported in the registry record. Since the posted binary comparison is not estimable, the observed effect needed for such planning cannot be interpreted as a reported treatment contrast.

What does the missing comparison imply?

The registry record contains group-level counts but no analysis results for a two-arm binary comparison. This is why the descriptive counts should not be converted into claims about superiority, equivalence or non-inferiority. A suitable estimate would need a prespecified comparison, a clear definition of the endpoint and a method for handling small samples and any missing observations. These details are not reported in the registry record. The study’s randomized structure is relevant to its intended comparison, but randomization alone does not substitute for reported analysis results.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("RZL-012 Cohort 1", "Vehicle", "RZL-012 Cohort 2", "Vehicle Cohort 2")
n      <- c(8, 4, 10, 6)
events <- c(8, 4, 10, 6)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  RZL-012 Cohort 1  8  8  100.0  63.1  100.0  67.6  100.0  66.4  99.7
ARM  Vehicle  4  4  100.0  39.8  100.0  51.0  100.0  47.8  99.5
ARM  RZL-012 Cohort 2  10  10  100.0  69.2  100.0  72.2  100.0  71.5  99.8
ARM  Vehicle Cohort 2  6  6  100.0  54.1  100.0  61.0  100.0  59.0  99.6

11. Multiplicity, Missing Data and Analysis Populations

The registry lists one primary safety outcome and three secondary outcomes: physician’s global assessment, MRI volume reduction and face satisfaction. The secondary face-satisfaction measure is described as a score from 0 (Worst) to 100 (Best). Numerical results for the secondary outcomes are not reported in the registry record. The statistical plan for managing multiple outcomes, including whether any adjustment or hierarchy was specified, is not reported in the registry record.

Multiplicity matters because examining multiple outcomes or comparisons can increase the chance of a seemingly notable result arising by chance. General statistical approaches may control that risk through prespecified outcome hierarchies or adjustment procedures. The registry record does not report whether such procedures were used. With no secondary outcome estimates or tests posted, no conclusions can be drawn about their results or the handling of multiplicity.

The safety population is described as enrolled subjects who received study treatment, compared with placebo-treated subjects. This indicates an exposed population rather than a stated intention-to-treat analysis of all randomized participants. The number randomized, the number receiving treatment, and participant flow by group are not separately described beyond the posted group counts. The missing-data approach, including how absent follow-up or incomplete outcome records were handled, is not reported in the registry record.

These gaps affect interpretation. If participants with incomplete safety follow-up were excluded, the observed counts might not represent every randomized participant. The posted record does not establish whether there were such exclusions. The follow-up window is given as 0-84 days, but the completeness of observations across that interval is not reported in the registry record. No imputation method, sensitivity analysis or analysis-set definition beyond the safety-population description is reported.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 1% reporting threshold.

Most frequent non-serious adverse event terms

The serious adverse-event figures are counts of participants affected, read with the corresponding number at risk. The record reports 0 serious adverse events among 8 at risk in RZL-012 Cohort 1, 0 among 4 in Vehicle Cohort 1, 0 among 10 in RZL-012 Cohort 2 and 0 among 6 in Vehicle Cohort 2. It also reports 0 deaths in each group. No serious adverse-event terms are listed.

These figures mean that no serious adverse events or deaths were recorded in the posted groups. They do not establish that serious events cannot occur, and they do not show that the treatments have equal serious-event risk. With no serious events in any group, a treatment contrast cannot be estimated from the posted serious-event counts. The registry record does not provide uncertainty intervals or a statistical comparison for these data.

Other adverse events are reported separately, with every participant in each group listed as affected. The record does not specify the individual event terms or provide enough detail to determine whether events were mild, temporary, related to treatment, or clinically consequential. A count of participants affected is not a count of all event episodes. Interpret the figures as a summary of events recorded during the specified follow-up, not as a complete safety profile.

13. What the Result Does, and Does Not, Mean

The posted results document the distribution of recorded safety events among participants in a randomized, single-blind, placebo-controlled study with two cohorts. No serious adverse events or deaths are reported in any group, while all participants in each group are reported as affected by other adverse events. These statements describe the registry counts and their denominators; they are not a statistical demonstration that RZL-012 and placebo have the same safety profile.

The findings do not establish whether RZL-012 caused any particular event. The registry record does not give event-level descriptions for the other adverse events, detailed assessments of relatedness, or comparative effect estimates. Nor does it report uncertainty intervals or inferential test results for the primary safety outcome. The number of participants and the absence of serious events limit what can be concluded about uncommon outcomes.

The results also do not answer whether RZL-012 reduces submental fat. The registry lists MRI volume reduction and physician’s global assessment as secondary outcomes, as well as a face-satisfaction score, but numerical results are not reported in the registry record. A safety outcome cannot substitute for an efficacy result, and the trial’s listed outcomes should not be treated as findings when the numerical estimates are absent.

Any interpretation is limited to the recorded groups, the healthy-volunteer population and the 0-84 days follow-up window. The record does not provide longer-term follow-up, detailed participant flow or information about how missing observations were handled. The sensible conclusion is a descriptive one: the registry records no serious events or deaths in these groups and records other adverse events among all participants, but it does not provide the comparative analysis needed to quantify differences between treatments.

14. Why This Trial Matters Statistically

This study illustrates why group counts and treatment comparisons are not interchangeable. The registry reports participant counts in four groups, preserving the distinction between the two cohorts and their different RZL-012 doses. That structure is important for interpretation: a count in one cohort should not automatically be treated as if it came from the same regimen as a count in the other cohort.

It also illustrates the limits of zero-event summaries. Zero serious events in each group is a clear description of what was recorded, but it does not imply that the underlying risk is absent or that the groups are equivalent. A comparison requires an effect estimate and a measure of its uncertainty. Neither is reported for the primary binary outcome.

The record further highlights the importance of specifying what a safety count represents. A number of participants affected is not the same as a number of event episodes, and it does not reveal the type, severity or timing of each event. Detailed outcome definitions and participant flow help readers distinguish a complete follow-up assessment from an incomplete one; those details are not fully.

Finally, this trial shows why efficacy and safety outcomes must be interpreted separately. Secondary efficacy-related outcomes are listed, but their numerical results are not reported in the registry record. Their presence in the outcome list does not establish that a benefit was observed. Statistically, the record is most informative as a compact description of the planned safety question and the counts posted, while leaving treatment-effect estimation and precision unresolved.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The posted results have important trial-specific limitations. The study enrolled 28 participants across two cohorts and four treatment groups, so the group counts are small. In particular, zero serious events across the groups cannot provide a precise estimate of uncommon serious-event risk. The registry record does not provide confidence intervals or another uncertainty measure for these counts.

The two RZL-012 cohorts used different doses, and the record does not report a comparative analysis that accounts for cohort. Pooling or directly comparing groups without addressing that structure could obscure differences in dose or cohort conditions. The detailed dose instructions are not fully reported in the registry record. The randomization procedure, allocation concealment and identity of the blinded party are also not reported in the registry record.

For other adverse events, all participants are listed as affected, but event terms, severity, duration, timing and treatment relatedness are not reported in the registry record. The participant-level count does not show how many event episodes occurred. It is also unclear how the broad safety outcome relates to each named symptom in the outcome description.

There is no posted inferential analysis for the primary endpoint, and numerical results for the listed secondary outcomes are not reported. The analysis plan, multiplicity approach, missing-data methods and detailed participant flow are not reported in the registry record. The record identifies an exposed safety population but does not give a full account of randomized participants who may not have received treatment or completed follow-up. Finally, the specified follow-up ends at 0-84 days; longer-term outcomes are not reported in the registry record.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers. — NCT04086823.
• Registry record last updated 2023-11-18; status last verified 2019-09.
• Results first posted 2023-11-18.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes a completed, randomized, single-blind, parallel-group Phase 2a study of RZL-012 versus placebo in healthy volunteers with submental fat. Enrollment was 28, with two cohorts and four posted outcome groups. The primary safety outcome covered 0-84 days and was assessed through spontaneous adverse-event reports and post-injection evaluations.

The record reports 0 serious adverse events and 0 deaths in each group. It reports other adverse events affecting all participants represented in each group. A treatment comparison, uncertainty estimates and numerical secondary-outcome results are not reported in the registry record. The findings therefore support a descriptive account of the posted safety counts, but not a quantified treatment contrast or an efficacy conclusion.